Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
暂无分享,去创建一个
J. J. Spadaro | E. Topol | M. Weisfeldt | H. Gold | J. Fallon | J. Guerrero | J. Brinker | A. Hutter | T. Yasuda | R. Leinbach | J. Newell | B. Khaw | D. Collen | A. Robison | A. Tiefenbrunn | E. Grossbard | F. Vislosky | C. Hoyng | W. Bell | Ludbrook | B. Sobel | B. H. Bulkley | A. Philip | Isunehiro | Yasuda
[1] B E Sobel,et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.
[2] D. Pennica,et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. , 1984, The Journal of pharmacology and experimental therapeutics.
[3] B. Sobel,et al. Thrombolysis, clot selectivity, and kinetics. , 1984, Circulation.
[4] T. Venable,et al. Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. , 1984, Circulation.
[5] F. Van de Werf,et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. , 1984, The New England journal of medicine.
[6] R. Schröder. Intravenous short-term infusion of streptokinase in acute myocardial infarction. , 1984, International journal of cardiology.
[7] B. Sobel,et al. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. , 1984, Circulation.
[8] R. Lijnen,et al. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. , 1984, The Journal of biological chemistry.
[9] R. C. Reeves,et al. Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction. , 1983, Circulation.
[10] I. Palacios,et al. Coronary reocclusion after selective administration of streptokinase. , 1983, Circulation.
[11] M. Verstraete,et al. Systemic thrombolytic therapy of acute myocardial infarction? , 1983, Circulation.
[12] M. Ter-pogossian,et al. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. , 1983, Science.
[13] P. R. Frederick,et al. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. , 1983, The New England journal of medicine.
[14] W. O’Neill,et al. Intracoronary fibrinolytic therapy in acute myocardial infarction. Report of a prospective randomized trial. , 1983, The New England journal of medicine.
[15] H. Kreuzer,et al. Intravenöse Streptokinase-Kurzinfusion beim akuten Myokardinfarkt , 1983 .
[16] M. Verstraete,et al. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. , 1983, The Journal of clinical investigation.
[17] P. Seeburg,et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.
[18] A. Billiau,et al. Purification of Human Tissue-Type Plasminogen Activator in Centigram Quantities from Human Melanoma Cell Culture Fluid and Its Conditioning for Use In Vivo , 1982, Thrombosis and Haemostasis.
[19] M. Hoylaerts,et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.
[20] C. Korninger,et al. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. , 1982, The Journal of clinical investigation.
[21] J. Fallon. Postmortem: Histochemical Techniques , 1982 .
[22] W. Weimar,et al. SPECIFIC LYSIS OF AN ILIOFEMORAL THROMBUS BY ADMINISTRATION OF EXTRINSIC (TISSUE-TYPE) PLASMINOGEN ACTIVATOR , 1981, The Lancet.
[23] T. Heinze,et al. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator? , 1981, Archives of biochemistry and biophysics.
[24] C. Korninger,et al. Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits , 1981, Thrombosis and Haemostasis.
[25] O. Matsuo,et al. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus , 1981, Nature.
[26] P. Rentrop,et al. Selective Intracoronary Thrombolysis in Acute Myocardial Infarction and Unstable Angina Pectoris , 1981, Circulation.
[27] W. Ganz. Intracoronary thrombolysis in evolving myocardial infarction. , 1981, Annals of internal medicine.
[28] M S Golden,et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.
[29] R. Jennings,et al. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979, Laboratory investigation; a journal of technical methods and pathology.
[30] J. Lowe,et al. The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.
[31] P. Gaffney,et al. The sulphite precipitation method for fibrinogen measurement; its use on small samples in the presence of fibrinogen degradation products. , 1976, Clinica chimica acta; international journal of clinical chemistry.
[32] P. Lalezari,et al. A Rapid, Simple, Sensitive Method for Measuring Fibrinolytic Split Products in Human Serum∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[33] A. Clauss,et al. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .